Keratoconus is a progressive inherited disorder with varying economic and social consequences. Varying modalities of visual rehabilitation such as spectacles, contact lenses, surgical treatment in the form of corneal collagen cross-linking to arrest progression, and surface refractive procedures such as photorefractive keratectomy, implantation of phakic intraocular lenses (IOLs), or Intacs have been undertaken with varying results. This
INTRODUCTION
Keratoconus is a noninflammatory, progressive ectatic disorder of the cornea, thus inducing myopic irregular astigmatism causing a decrease in visual acuity. 1, 2 Visual rehabilitation in the form of spectacles and contact lenses is given with varying success at the different stages of the disease. To halt the progression of the disease, corneal collagen cross-linking (CXL) is the only option available. Various studies have established the role of CXL to prevent the progression of keratoconus. [3] [4] [5] [6] [7] Cross-linking has been used as the modality to prevent progression of keratoconus alone or in combination with photorefractive keratectomy (PRK), 8, 9 Intacs, 10,11 implantable contact lenses (ICLs), 12, 13 etc. Phakic intraocular lens (PIOL) or ICL has been introduced as a treatment option to correct the refractive error to the optimal in keratoconus patients. This review article discusses the ICL, their risks and benefits, and results in keratoconus patients in various situations.
IMPLANTABLE CONTACT LENSES
Phakic IOLs or ICLs are a special kind of intraocular lenses behind the natural lens of the patient to treat myopic, hyperopic, or astigmatic refractive errors to provide high-quality vision to the patient. 14,15
• Increase in intraocular pressure postoperatively either because of retained viscoelastic substance or because of increased vault of the IOL causing pupillary block.
• Can cause glare and haloes.
• Endothelial cell loss annually. A study observed a continual steady loss of endothelial cells of -1.8% per year.
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ICL IN KERATOCONUS
The use of ICL in keratoconus started in 2008. In an early study conducted on two patients having contact lens intolerance, stable topography, and refraction, phakic toric ICL implantation improved the uncorrected and best spectacle-corrected visual acuity (UCVA and BSCVA) markedly. Preoperatively, the manifest refraction was -10.00 -6.00 × 100 in case 1 and -8.00 -2.75 × 100 in case 2. Postoperatively, the manifest refraction was +0.50 -1.00 × 90 in case 1 and -0.25 -1.25 × 100 in case 2.
No progression of keratoconus was observed till 1 year of follow-up. 16 In a prospective, noncomparative interventional case series, significant increase in BSCVA was observed after implantation of STAAR collamer posterior chamber PIOL. This established the fact that ICL implantation can be considered as a safe, effective, and predictable procedure for the correction of refractive error in keratoconus patients. 17 In further prospective study conducted on 30 eyes of 21 patients, it was well established that toric ICL implantation is a predictable, effective procedure to correct ametropia in eyes with keratoconus. Results were fairly stable up to a follow-up of 12 months. Preoperatively, the mean spherical equivalent (SE) in the 30 eyes (21 patients) was -5.38 D ± 3.26 (standard deviation, SD) (-13.50 to -0.63 D) and the mean cylinder -3.48 ± 1.24 D ( -1.75 to -6.00 D). At 12 months, 86.7% of the eyes were within ± 0.50 D of the attempted refraction and all eyes were within ±1.00 D. 18 In another study conducted on 27 keratoconus patients with implantation of toric ICL STAAR surgical, it was observed that throughout a period of 6 months follow-up, toric ICL implantation was good in terms of safety, predictability, efficacy, and stability. All patients had mild keratoconus with SE of -10 ± 2.46 D and astigmatism of -3 ± 1.58 D. LogMAR UCVA and logMAR BSCVA values were -0.09 ± 0.16 and -0.15 ± 0.09 respectively, 6 months after surgery. The safety and efficacy indices were 1.12 ± 0.18 and 1.01 ± 0.25. At 6 months, 85 and 96% of the eyes were within ± 0.5 and ± 1.0 D, respectively, of the targeted correction. 19 Similar lens was evaluated in another subset of keratoconus patients conforming the previous results. In this study, 22 eyes of 14 patients were evaluated. The mean preoperative SE and cylinder changed from -4.98 ± 2.63 DS and -2.77 ± 0.99 DC to -0.33 ± 0.51 DS and -1.23 ± 0.65 DC respectively at the end of 6 months. Before the surgery, the mean Snellen decimal visual acuity was 0.63 ± 0.20. The mean unaided vision and visual acuity changed to 0.76 ± 0.23 and 0.85 ± 0.21 respectively at the end of 6 months. The mean safety and efficacy indices were 1.40 ± 0.32 and 1.24 ± 0.34 respectively. 20 In another study with a long follow-up of 3 years, it was observed that toric ICL implantation is a good treatment option with safety, efficacy, and predictability. Results were stable over follow-up of 3 years. This was a retrospective study conducted on 21 eyes of 11 patients with SEs of -9.70 ± 2.33 D (mean ± SD) and astigmatism of -3.21 ± 1.56 D. At 3 years, 67 and 86% of the eyes were within ± 0.5 and ± 1.0 D respectively of the targeted correction.
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Efficacy of toric ICL implantation has been evaluated even in keratoconic eyes after CXL. In a case report evaluating ICL implantation subsequent to CXL after 6 months, it was observed that collamer lens implantation in a two-step procedure seems to be an effective method for correcting keratoconus in patients with high myopia and astigmatism. In this study, a 22-year-old female patient underwent posterior chamber PIOL implantation, 12 months after CXL. It was observed that 3 months after the surgery, UCVA improved from counting fingers to 20/40 and corrected distance visual acuity (CDVA) improved from 20/100 to 20/30. 22 In another prospective study evaluating keratoconus patients undergoing topographyguided PRK with CXL, followed by implantation of iris claw or angle-supported PIOLs, it was established that combining the two procedures improved the visual performance in keratoconus patients. In this study, 22 eyes of 14 patients, who underwent PIOL implantation 3 to 4 months after simultaneous topography-guided PRK and CXL, were evaluated. The mean SE was significantly reduced from -9.08 ± 2.5 to -0.69 ± 0.67 D, p ≤ 0.001. The mean UCVA improved from 1.24 ± 0.49 to 0.37 ± 0.08 logMAR. The mean CDVA (logMAR) improved from 0.69 ± 0.3 preoperatively to 0.35 ± 0.01 postoperatively (p ≤ 0.001). At last follow-up, all eyes could achieve CDVA of 0.3 or better. 23 Implantation of toric ICL in keratoconus patients has been evaluated even for the residual refractive error after Intacs implantation and CXL, suggesting that ICL can serve as a good treatment option for the residual refractive error in such patients. 24, 25 In another study conducted on 16 eyes with keratoconus ICL implantation after CXL, results were observed to be fairly stable even after long-term follow-up of 3 years, with no significant endothelial cell loss. The mean Snellen decimal CDVA improved from 0.56 ± (p < 0.0001). The mean UDVA also improved significantly from 0.63 ± 0.14 before ICL
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implantation to 0.88 ± 0.18 after 3 years of follow-up (p < 0.001). The endothelial cell count loss after 3 years was -8.98%. 26 Angle-supported PIOLs were also evaluated in keratoconus stages I and II. This study was conducted on 12 eyes of 8 patients. The UCVA was 20/40 or better in all cases. The BSCVA was equal or improved in all cases. The safety index (postoperative BSCVA/preoperative BSCVA) was 1.18; the efficacy index (postoperative UCVA/ preoperative BSCVA) was 0.77. 27 It was observed that anglesupported PIOLs serve as an effective treatment option for early stage keratoconus. In another study involving combined implantation of kerarings and Artisan/Artiflex PIOLs in patients with varying causes of corneal ectasia such as keratoconus, pellucid marginal degeneration resulted in visual and refractive improvements. This study involved 10 eyes of 8 patients, and it was observed that mean UDVA improved from 0.02 ± 0.10 preoperatively to 0.11 ± 0.06 after Keraring implantation and to 0.54 ± 0.18 after PIOL implantation (p < 0.001 for all). Mean CDVA improved from 0.18 ± 0.12 preoperatively to 0.39 ± 0. The BCDVA changes were not significant (0.09 ± 0.11 vs 0.05 ± 0.08). 30 In another study undertaken on 20 eyes of 14 patients who underwent collamer lens implantation for keratoconus with a follow-up of 1 year, it was observed that 90% of the eyes had refractive cylinder of <1.0 D (p = 0.003) and 100% of eyes were within ± 0.75 D of sphere at 1 year (p = 0.0085). The safety index at 12 months was 1.2.
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CONCLUSION
Keratoconus with high myopic and irregular astigmatism causes a lot of visual morbidity to the patients. Various treatment options have been provided for the visual rehabilitation of keratoconus patients. Implantable contact lenses have emerged as a good treatment option for such patients with high degree of efficacy, safety, and predictability. Various studies have established this fact. Implantable contact lenses have been implanted in keratoconus patients in various combinations with CXL, Intacs, or after keratoplasty to provide optimal visual rehabilitation in such patients.
